{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:41:32Z","timestamp":1789094492819,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04044-x","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T08:56:49Z","timestamp":1741337809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A comprehensive evaluation of Naftifine's efficacy and safety in treating dermatophyte infections; systematic review and meta-analysis"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8165-9470","authenticated-orcid":false,"given":"Mohamed","family":"Abo Zeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elrosasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazim","family":"Alkousheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashad G.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa M.","family":"AlEdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamdy","family":"Zabady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah S.","family":"Alhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel Hussain","family":"Alhussainy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa Sayed Suliman","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"4044_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4103\/2229-5178.178099","volume":"7","author":"A Sahoo","year":"2016","unstructured":"Sahoo A, Mahajan R (2016) Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol Online J 7:77","journal-title":"Indian Dermatol Online J"},{"key":"4044_CR2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1128\/CMR.8.2.240","volume":"8","author":"I Weitzman","year":"1995","unstructured":"Weitzman I, Summerbell RC (1995) The dermatophytes. Clin Microbiol Rev 8:240\u2013259","journal-title":"Clin Microbiol Rev"},{"key":"4044_CR3","first-page":"702","volume":"90","author":"JW Ely","year":"2014","unstructured":"Ely JW, Rosenfeld S, Stone MS (2014) Diagnosis and management of tinea infections. Am Fam Physician 90:702\u2013710","journal-title":"Am Fam Physician"},{"key":"4044_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2023-8-2","volume":"12","author":"AKC Leung","year":"2023","unstructured":"Leung AKC, Barankin B, Lam JM, Leong KF, Hon KL (2023) Tinea pedis: an updated review. Drugs Context 12:1\u201316","journal-title":"Drugs Context"},{"key":"4044_CR5","unstructured":"Centers for Disease Control and Prevention (CDC). (2024). Clinical Overview of Ringworm (Tinea) for Healthcare Professionals. https:\/\/www.cdc.gov\/ringworm\/hcp\/clinical-overview\/index.html. Accessed Feb 15, 2024."},{"key":"4044_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40261-023-01288-1","volume":"43","author":"SD Sinha","year":"2023","unstructured":"Sinha SD, Rajamma A, Bandi MR et al (2023) Efficacy and safety of naftifine hydrochloride 2% gel in interdigital tinea pedis: a phase III randomised, double-blind, parallel-group, active-controlled study in Indian adult patients. Clin Drug Investig 43:565\u2013574","journal-title":"Clin Drug Investig"},{"key":"4044_CR7","first-page":"1282","volume":"10","author":"LC Parish","year":"2011","unstructured":"Parish LC, Parish JL, Routh HB, Fleischer AB, Avakian EV, Plaum S, Hardas B (2011) A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol 10:1282\u20131288","journal-title":"J Drugs Dermatol"},{"key":"4044_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0190-9622(08)80528-2","volume":"26","author":"EB Smith","year":"1992","unstructured":"Smith EB, Breneman DL, Griffith RF et al (1992) Double-blind comparison of naftifine cream and clotrimazole\/betamethasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol 26:125\u2013127","journal-title":"J Am Acad Dermatol"},{"key":"4044_CR9","first-page":"s56","volume":"15","author":"TC Vlahovic","year":"2016","unstructured":"Vlahovic TC (2016) The role of naftifine HCl 2% gel and cream in treating moccasin tinea pedis. J Drugs Dermatol 15:s56\u2013s59","journal-title":"J Drugs Dermatol"},{"key":"4044_CR10","first-page":"1138","volume":"14","author":"LFS Gold","year":"2015","unstructured":"Gold LFS, Vlahovic T, Verma A, Olayinka B, Fleischer AB (2015) Naftifine hydrochloride Gel 2%: an effective topical treatment for moccasin-type tinea pedis. J Drugs Dermatol 14:1138\u20131144","journal-title":"J Drugs Dermatol"},{"key":"4044_CR11","first-page":"686","volume":"14","author":"A Verma","year":"2015","unstructured":"Verma A, Olayinka B, Fleischer AB (2015) An open-label, multi-center, multiple-application pharmacokinetic study of naftifine hcl gel 2% in pediatric subjects with tinea pedis. J Drugs Dermatol 14:686\u2013691","journal-title":"J Drugs Dermatol"},{"key":"4044_CR12","first-page":"162","volume":"13","author":"LH Kircik","year":"2014","unstructured":"Kircik LH, Onumah N (2014) Use of naftifine hydrochloride 2% cream and 39% urea cream in the treatment of tinea pedis complicated by hyperkeratosis. J Drugs Dermatol 13:162\u2013165","journal-title":"J Drugs Dermatol"},{"key":"4044_CR13","first-page":"743","volume":"15","author":"M Gold","year":"2016","unstructured":"Gold M, Dhawan S, Verma A, Kuligowski M, Dobrowski D (2016) Efficacy and safety of naftifine HCl cream 2% in the treatment of pediatric subjects with tinea corporis. J Drugs Dermatol 15:743\u2013748","journal-title":"J Drugs Dermatol"},{"key":"4044_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000084436","volume":"74","author":"IA Ar\u0131do\u011fan","year":"2005","unstructured":"Ar\u0131do\u011fan IA, Ate\u015f A, \u0130zol V, \u0130lkit M (2005) Tinea cruris in routine urology practice. Urol Int 74:346\u2013348","journal-title":"Urol Int"},{"key":"4044_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00128071-200405060-00009","volume":"5","author":"AA Kyle","year":"2004","unstructured":"Kyle AA, Dahl MV (2004) Topical therapy for fungal infections. Am J Clin Dermatol 5:443\u2013451","journal-title":"Am J Clin Dermatol"},{"key":"4044_CR16","first-page":"1218","volume":"59","author":"F Klaschka","year":"1984","unstructured":"Klaschka F, Gartmann H, Weidinger G (1984) The antifungal agent naftifin. Placebo-controlled therapeutic comparison in tinea pedis. Z Hautkr 59:1218\u20131226","journal-title":"Z Hautkr"},{"key":"4044_CR17","first-page":"677","volume":"103","author":"A Bojanovsky","year":"1985","unstructured":"Bojanovsky A, Haas P (1985) Antimycotic effect of naftifin in tinea pedis. Comparative double-blind study with bifonazole. Fortschr Med 103:677\u2013679","journal-title":"Fortschr Med"},{"key":"4044_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13708","author":"D Kolarczykov\u00e1","year":"2024","unstructured":"Kolarczykov\u00e1 D, Lyskov\u00e1 P, \u0160varcov\u00e1 M, Kuklov\u00e1 I, Dobi\u00e1\u0161 R, Mall\u00e1tov\u00e1 N, Kola\u0159\u00edk M, Hubka V (2024) Terbinafine resistance in Trichophyton mentagrophytes and Trichophyton rubrum in the Czech Republic: A prospective multicentric study. Mycoses. https:\/\/doi.org\/10.1111\/myc.13708","journal-title":"Mycoses"},{"key":"4044_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Moher D (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103\u2013112","journal-title":"J Clin Epidemiol"},{"key":"4044_CR20","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ (2019) Cochrane handbook for systematic reviews of interventions, sixth.","DOI":"10.1002\/9781119536604"},{"key":"4044_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5:210","journal-title":"Syst Rev"},{"key":"4044_CR22","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898\u2013l4898","DOI":"10.1136\/bmj.l4898"},{"key":"4044_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF03259542","volume":"3","author":"RL Dobson","year":"1991","unstructured":"Dobson RL, Bagatell FK, Hickman JG, Whitmore CG, Willis I, Seffon J, DeGryse RE (1991) Naftifine 1% cream in the treatment of tinea cruris and tinea corporis. Drug Investig 3:57\u201359","journal-title":"Drug Investig"},{"key":"4044_CR24","first-page":"911","volume":"12","author":"LFS Gold","year":"2013","unstructured":"Gold LFS, Parish LC, Vlahovic T, Plaum S, Kircik L, Fleischer AB, Verma A, Olayinka B, Hardas B (2013) Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. J Drugs Dermatol 12:911\u2013918","journal-title":"J Drugs Dermatol"},{"key":"4044_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-4362.1990.tb03835.x","volume":"29","author":"RE Jordon","year":"1990","unstructured":"Jordon RE, Rapini RP, Rex IH et al (1990) Once-daily naftifine cream 1% in the treatment of tinea cruris and tinea corporis. Int J Dermatol 29:441\u2013442","journal-title":"Int J Dermatol"},{"key":"4044_CR26","first-page":"1142","volume":"10","author":"LC Parish","year":"2011","unstructured":"Parish LC, Parish JL, Routh HB, Avakian E, Olayinka B, Pappert EJ, Plaum S, Fleischer AB, Hardas B (2011) A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol 10:1142\u20131147","journal-title":"J Drugs Dermatol"},{"key":"4044_CR27","doi-asserted-by":"crossref","unstructured":"Nada M, Hanafi S, al-Omari H, Mokhtar M, el-Shamy S, M\u00fchlbacher J (1994) Naftifine versus miconazole\/hydrocortisone in inflammatory dermatophyte infections. Int J Dermatol 33:570\u2013572","DOI":"10.1111\/j.1365-4362.1994.tb02899.x"},{"key":"4044_CR28","doi-asserted-by":"crossref","unstructured":"el Darouti MA, al Raubaie S, Shandrashekhar CR, al Sawaf MH, Movahadi GA (1989) Double-blind randomized comparative study of naftifine cream and clotrimazole cream in the treatment of dermatophytosis. Int J Dermatol 28:345\u2013346","DOI":"10.1111\/j.1365-4362.1989.tb01362.x"},{"key":"4044_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0190-9622(88)70008-0","volume":"18","author":"LE Millikan","year":"1988","unstructured":"Millikan LE, Galen WK, Gewirtzman GB, Horwitz SN, Landow RK, Nesbitt LT, Roth HL, Sefton J, Day RM (1988) Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol 18:52\u201356","journal-title":"J Am Acad Dermatol"},{"key":"4044_CR30","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaad.2021.11.065","volume":"86","author":"FF Muhaj","year":"2022","unstructured":"Muhaj FF, George SJ, Nguyen CD, Tyring SK (2022) Antimicrobials and resistance part II: antifungals, antivirals, and antiparasitics. J Am Acad Dermatol 86:1207\u20131226","journal-title":"J Am Acad Dermatol"},{"key":"4044_CR31","doi-asserted-by":"crossref","unstructured":"Patro N, Suryatale PR, Pandya I, Mian NZ, Chinda M, M. Daultani P, Mittal R, D. Jaiswal A, Singh A (2024) A phase III randomized controlled clinical trial evaluating the efficacy and safety of naftifine 2% cream versus terbinafine 1% cream in patients with superficial fungal infection of the skin. International Journal of Research in Dermatology 10:170\u2013176","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20241599"},{"key":"4044_CR32","doi-asserted-by":"publisher","unstructured":"Jartarkar SR, Patil A, Goldust Y, Cockerell CJ, Schwartz RA, Grabbe S, Goldust M (2021) Pathogenesis, Immunology and Management of Dermatophytosis. J Fungi (Basel). https:\/\/doi.org\/10.3390\/jof8010039","DOI":"10.3390\/jof8010039"},{"key":"4044_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3736","author":"S Dogra","year":"2022","unstructured":"Dogra S, Ramam M (2022) Difficult dermatophytosis. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3736","journal-title":"JAMA Dermatol"},{"key":"4044_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1128\/AAC.47.1.82-86.2003","volume":"47","author":"PK Mukherjee","year":"2003","unstructured":"Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA (2003) Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother 47:82\u201386","journal-title":"Antimicrob Agents Chemother"},{"key":"4044_CR35","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/jof7110983","volume":"7","author":"R Sacheli","year":"2021","unstructured":"Sacheli R, Hayette M-P (2021) Antifungal resistance in dermatophytes: genetic considerations, clinical presentations and alternative therapies. J Fungi 7:983","journal-title":"J Fungi"},{"key":"4044_CR36","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.3390\/jcm13123558","volume":"13","author":"B Sonego","year":"2024","unstructured":"Sonego B, Corio A, Mazzoletti V, Zerbato V, Benini A, di Meo N, Zalaudek I, Stinco G, Errichetti E, Zelin E (2024) Trichophyton indotineae, an emerging drug-resistant dermatophyte: a review of the treatment options. J Clin Med 13:3558","journal-title":"J Clin Med"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04044-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04044-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04044-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T08:56:55Z","timestamp":1741337815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04044-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4044"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04044-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest associated with the conduct of this work. No conflicting relationship exists for any author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"522"}}